Related Experiment Video
Updated: Oct 8, 2025
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
Debajyoti Das1, Avishek Paul1, Sujay Krishna Maity1
1Division of Cell Biology and Physiology, CSIR-Indian Institute of Chemical Biology, 4 Raja SC Mullick Road, Kolkata, West Bengal 700032, India.
Abstract:
Here, we describe a robust protocol using mouse models to screen potential insulin-stabilizers and insulin moieties. We have generated a mouse model of amyloidoma, found in diabetic patients undergoing insulin therapy. This model can be used to screen potential insulin stabilizers and insulin moieties to prevent amyloidoma formation. This protocol can further be used for the preclinical validation of therapeutically relevant insulin stabilizers and formulations. The protocol highlights all the critical steps for generating amyloidoma in a preclinical model. For complete details on the use and execution of this profile, please refer to Mukherjee et al. (2021).
Insights
Researchers developed a mouse model to test insulin stabilizers and prevent amyloidoma, a condition seen in diabetic patients. This preclinical model aids in validating new insulin formulations for improved diabetes treatment.
Area of Science:
- Biomedical Research
- Pharmacology
- Endocrinology
Background:
- Diabetic patients on insulin therapy can develop amyloidoma.
- Current methods for screening insulin stabilizers are limited.
Purpose of the Study:
- To establish a robust mouse model for screening insulin stabilizers.
- To validate preclinical insulin formulations and moieties for preventing amyloidoma.
Main Methods:
- Generation of a mouse model mimicking amyloidoma formation.
- Utilizing the model for screening potential insulin stabilizers and moieties.
- Detailed protocol for amyloidoma induction in a preclinical setting.
Main Results:
- Successful generation of a mouse model of amyloidoma.
- Demonstration of the model's utility in screening insulin stabilizers.
- Protocol provides critical steps for preclinical validation.
Conclusions:
- The developed mouse model is effective for screening insulin stabilizers.
- This protocol facilitates the preclinical validation of insulin formulations.
- A valuable tool for advancing diabetes therapy and insulin stability.
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017